These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16030021)

  • 1. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells.
    Lynch MJ; Baillie GS; Mohamed A; Li X; Maisonneuve C; Klussmann E; van Heeke G; Houslay MD
    J Biol Chem; 2005 Sep; 280(39):33178-89. PubMed ID: 16030021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
    Baillie GS; Sood A; McPhee I; Gall I; Perry SJ; Lefkowitz RJ; Houslay MD
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):940-5. PubMed ID: 12552097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of beta2-adrenoceptor signalling to activation of ERK.
    Houslay MD; Baillie GS
    Biochem Soc Trans; 2005 Dec; 33(Pt 6):1333-6. PubMed ID: 16246112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.
    Bolger GB; Baillie GS; Li X; Lynch MJ; Herzyk P; Mohamed A; Mitchell LH; McCahill A; Hundsrucker C; Klussmann E; Adams DR; Houslay MD
    Biochem J; 2006 Aug; 398(1):23-36. PubMed ID: 16689683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays.
    Baillie GS; Adams DR; Bhari N; Houslay TM; Vadrevu S; Meng D; Li X; Dunlop A; Milligan G; Bolger GB; Klussmann E; Houslay MD
    Biochem J; 2007 May; 404(1):71-80. PubMed ID: 17288540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1.
    Smith KJ; Baillie GS; Hyde EI; Li X; Houslay TM; McCahill A; Dunlop AJ; Bolger GB; Klussmann E; Adams DR; Houslay MD
    Cell Signal; 2007 Dec; 19(12):2612-24. PubMed ID: 17900862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5.
    Li X; Baillie GS; Houslay MD
    J Biol Chem; 2009 Jun; 284(24):16170-16182. PubMed ID: 19372219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling.
    Lynch MJ; Baillie GS; Houslay MD
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):938-41. PubMed ID: 17956250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK).
    Baillie G; MacKenzie SJ; Houslay MD
    Mol Pharmacol; 2001 Nov; 60(5):1100-11. PubMed ID: 11641439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase-4 influences the PKA phosphorylation status and membrane translocation of G-protein receptor kinase 2 (GRK2) in HEK-293beta2 cells and cardiac myocytes.
    Li X; Huston E; Lynch MJ; Houslay MD; Baillie GS
    Biochem J; 2006 Mar; 394(Pt 2):427-35. PubMed ID: 16356165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins.
    Bolger GB; McCahill A; Huston E; Cheung YF; McSorley T; Baillie GS; Houslay MD
    J Biol Chem; 2003 Dec; 278(49):49230-8. PubMed ID: 14500724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ERK2 docking and phosphorylation of PDE4 cAMP phosphodiesterase isoforms in mediating cross-talk between the cAMP and ERK signalling pathways.
    Houslay MD; Baillie GS
    Biochem Soc Trans; 2003 Dec; 31(Pt 6):1186-90. PubMed ID: 14641023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palmitoylation regulates intracellular trafficking of β2 adrenergic receptor/arrestin/phosphodiesterase 4D complexes in cardiomyocytes.
    Liu R; Wang D; Shi Q; Fu Q; Hizon S; Xiang YK
    PLoS One; 2012; 7(8):e42658. PubMed ID: 22912718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region.
    McCahill A; McSorley T; Huston E; Hill EV; Lynch MJ; Gall I; Keryer G; Lygren B; Tasken K; van Heeke G; Houslay MD
    Cell Signal; 2005 Sep; 17(9):1158-73. PubMed ID: 15905070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel protein kinase A-independent, beta-arrestin-1-dependent signaling pathway for p38 mitogen-activated protein kinase activation by beta2-adrenergic receptors.
    Gong K; Li Z; Xu M; Du J; Lv Z; Zhang Y
    J Biol Chem; 2008 Oct; 283(43):29028-36. PubMed ID: 18678875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins.
    Perry SJ; Baillie GS; Kohout TA; McPhee I; Magiera MM; Ang KL; Miller WE; McLean AJ; Conti M; Houslay MD; Lefkowitz RJ
    Science; 2002 Oct; 298(5594):834-6. PubMed ID: 12399592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An anchored PKA and PDE4 complex regulates subplasmalemmal cAMP dynamics.
    Willoughby D; Wong W; Schaack J; Scott JD; Cooper DM
    EMBO J; 2006 May; 25(10):2051-61. PubMed ID: 16642035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
    MacKenzie SJ; Houslay MD
    Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase-4 gates the ability of protein kinase A to phosphorylate G-protein receptor kinase-2 and influence its translocation.
    Houslay MD; Baillie GS
    Biochem Soc Trans; 2006 Aug; 34(Pt 4):474-5. PubMed ID: 16856836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.
    Shenoy SK; Drake MT; Nelson CD; Houtz DA; Xiao K; Madabushi S; Reiter E; Premont RT; Lichtarge O; Lefkowitz RJ
    J Biol Chem; 2006 Jan; 281(2):1261-73. PubMed ID: 16280323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.